Literature DB >> 11874396

Patient reporting of potential adverse drug reactions: a methodological study.

N Jarernsiripornkul1, J Krska, P A G Capps, R M E Richards, A Lee.   

Abstract

AIMS: To develop a systematic generic method of enabling patients to report symptoms which they believe to be due to a particular prescribed drug.
METHODS: A piloted body system-based questionnaire was distributed to patients registered with 79 medical practices in Grampian prescribed one of nine recently marketed 'black triangle' drugs. These comprised four antidepressants, three antiepileptics and two analgesics. This requested respondents to identify any symptoms experienced over the previous year which they thought could be due to the 'black triangle' drug they had used. A sample of medical records was examined to compare symptoms recorded with those reported by patients. A classification system was developed for the study to enable the assessment of symptoms reported for their potential relationship to patients' drug therapy. All symptoms reported were classified, taking into account information provided by patients on their concomitant drugs and diseases. A specialist pharmacist independently re-classified a sample of the symptoms to validate the process.
RESULTS: A 36.3% response rate was obtained (837/2307) with 742 respondents (88.6%) reporting at least one symptom. The median per patient was 6.0 (range 0--71), with almost half (406, 48.5%) reporting fewer than five symptoms. Most symptoms (71.0%) were classified as being probably or possibly related to the drugs studied. Agreement between researcher and specialist on the classification of 75.3% of 716 symptoms was obtained (Kappa=0.563). Responses from patients prescribed antidepressant drugs were more likely to include symptoms potentially caused by these drugs (74.5% of all symptoms reported) than those from patients prescribed analgesics (67.4%) or antiepileptics (65.1%, chi2 = 23.858, d.f. = 2, P < 0.001). Patients reporting large numbers of symptoms were more likely to report some which were classed as unlikely to be an ADR or unattributable (chi2 = 80.587, d.f. = 3, P < 0.001). Of the 742 reporting symptoms in questionnaires, 402 (54.2%) claimed to have reported some or all of these to their doctor. Only 162 (22.6%) of 716 patient-reported symptoms were documented in the primary care medical records of 103 patients prescribed tramadol or venlafaxine.
CONCLUSIONS: Respondents were clearly willing to report symptoms, the majority of which were classed as possibly/probably related to the drugs studied. The results suggest that patients do not report all symptoms they suspect to be ADRs to their GP and that GPs do not record all symptoms which may be reported to them. The method could help to identify problems which patients perceive as being related to their drug therapy and contribute to increased ADR reporting.

Entities:  

Mesh:

Year:  2002        PMID: 11874396      PMCID: PMC1874308          DOI: 10.1046/j.0306-5251.2001.01547.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  Spontaneous reporting of adverse drug reactions. II: Uses.

Authors:  M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

2.  Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker.

Authors:  J Rosenthal; H Bahrmann; K Benkert; P Baumgart; G Bönner; G Klein; A Neiss; K Schnelle; E D Frohlich
Journal:  Cardiology       Date:  1996 Sep-Oct       Impact factor: 1.869

3.  Detection of adverse drug reactions in a clinical trial using two types of questioning.

Authors:  J Wallin; J Sjövall
Journal:  Clin Ther       Date:  1981       Impact factor: 3.393

4.  Patients' experiences of chemotherapy: side-effects of carboplatin in the treatment of carcinoma of the ovary.

Authors:  R Buckingham; J Fitt; J Sitzia
Journal:  Eur J Cancer Care (Engl)       Date:  1997-03       Impact factor: 2.520

5.  Patient drug attributions and postmarketing surveillance.

Authors:  S Fisher; S G Bryant; T A Kent; J E Davis
Journal:  Pharmacotherapy       Date:  1994 Mar-Apr       Impact factor: 4.705

Review 6.  Drug-related hospital admissions.

Authors:  T R Einarson
Journal:  Ann Pharmacother       Date:  1993 Jul-Aug       Impact factor: 3.154

7.  Patient-perceived side effects to antihypertensive drugs.

Authors:  J D Curb; N O Borhani; T P Blaszkowski; N Zimbaldi; S Fotiu; W Williams
Journal:  Am J Prev Med       Date:  1985 Jan-Feb       Impact factor: 5.043

8.  Patient-initiated postmarketing surveillance: a validation study.

Authors:  S Fisher; S G Bryant; B L Solovitz; R M Kluge
Journal:  J Clin Pharmacol       Date:  1987-11       Impact factor: 3.126

9.  Patients as a direct source of information on adverse drug reactions.

Authors:  A S Mitchell; D A Henry; R Sanson-Fisher; D L O'Connell
Journal:  BMJ       Date:  1988-10-08

10.  Involving the patient in reporting adverse drug reactions.

Authors:  J P Campbell; J G Howie
Journal:  J R Coll Gen Pract       Date:  1988-08
View more
  35 in total

1.  The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.

Authors:  Claire Anderson; Janet Krska; Elizabeth Murphy; Anthony Avery
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 2.  Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

Authors:  A Blenkinsopp; P Wilkie; M Wang; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

3.  Undesirable effects related to oral antineoplastic drugs: comparison between patients' internet narratives and a national pharmacovigilance database.

Authors:  Arnaud Pages; Emmanuelle Bondon-Guitton; Jean Louis Montastruc; Haleh Bagheri
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

4.  Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.

Authors:  Nataporn Chaipichit; Janet Krska; Thongchai Pratipanawatr; Narumol Jarernsiripornkul
Journal:  Int J Clin Pharm       Date:  2015-01-29

5.  Identifying Adverse Drug Events in Older Community-Dwelling Patients.

Authors:  Caitriona Cahir; Emma Wallace; Anthony Cummins; Conor Teljeur; Catherine Byrne; Kathleen Bennett; Tom Fahey
Journal:  Ann Fam Med       Date:  2019-03       Impact factor: 5.166

Review 6.  Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments.

Authors:  Ramandeep Basra; Con Kelleher
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Adverse Drug Reactions in Children--International Surveillance and Evaluation (ADVISE): a multicentre cohort study.

Authors:  Asia N Rashed; Ian C K Wong; Noel Cranswick; Barbara Hefele; Stephen Tomlin; John Jackman; Kenneth Lee; Kam-Lun E Hon; Jeffrey Ong; Maisoon Ghaleb; Siew Siang Chua; Tea Ming Hui; Wolfgang Rascher; Antje Neubert
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

8.  Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients.

Authors:  Caitriona Cahir; Kathleen Bennett; Conor Teljeur; Tom Fahey
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

9.  Patients' use of information about medicine side effects in relation to experiences of suspected adverse drug reactions: a cross-sectional survey in medical in-patients.

Authors:  Janet Krska; Charles W Morecroft
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

10.  Patient self-reporting of potential adverse drug reactions to non-steroidal anti-inflammatory drugs in Thailand.

Authors:  Narumol Jarernsiripornkul; Sudarat Chaisrisawadsuk; Aporanee Chaiyakum; Janet Krska
Journal:  Pharm World Sci       Date:  2009-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.